J&J's Tec-Tal Bispecific Combo Cuts Myeloma Progression Risk by 89% in Phase 3: What the Topline MonumenTAL-6 Data Show

What This Article Covers

On July 23, 2026, Johnson & Johnson announced topline results from the Phase 3 MonumenTAL-6 trial showing that combining two of its already-approved bispecific antibodies, TECVAYLI (teclistamab) and TALVEY (talquetamab), cut the risk of disease progression or death by 89 percent compared with standard-of-care regimens in patients with relapsed or refractory multiple myeloma who had already been treated with an anti-CD38 antibody and lenalidomide. A second experimental arm pairing TALVEY with pomalidomide also beat standard care, reducing progression risk by 73 percent. This article walks through what the two bispecifics do, what MonumenTAL-6 actually tested and found, what J&J has and has not yet disclosed, and what would still need to happen before this combination could reach patients as an approved regimen.

How TECVAYLI and TALVEY Work, and Why Pairing Them Is Notable

TECVAYLI (teclistamab-cqyv) and TALVEY (talquetamab-tgvs) are both “bispecific” antibodies, a category of engineered proteins built with two different binding arms. One arm locks onto a target on the surface of a patient's myeloma cells, and the other arm grabs onto CD3, a marker found on T cells, physically dragging a T cell up against the cancer cell so it can attack. Bispecifics are sometimes described as an “off-the-shelf” alternative to CAR-T cell therapy: rather than removing a patient's T cells, re-engineering them in a lab, and infusing them back weeks later, a bispecific is simply injected, working with the T cells already circulating in the patient's body.

The two drugs differ in which myeloma-cell target they grab. TECVAYLI, first approved by the FDA in October 2022, binds BCMA (B-cell maturation antigen), a protein expressed on the surface of malignant plasma cells. TALVEY, approved in August 2023, binds GPRC5D, a different plasma-cell-surface protein. Because they target distinct antigens, the two drugs also fail differently: myeloma cells that mutate or downregulate BCMA to escape TECVAYLI can, in principle, still be reachable by TALVEY's GPRC5D-directed arm, and vice versa. Combining both bispecifics at once, engaging two separate T-cell-recruiting mechanisms against two separate tumor targets simultaneously, was designed to reduce the chances that the cancer's escape route from one drug remains open under the other.

MonumenTAL-6: The Trial and the Topline Numbers

MonumenTAL-6 (registered on ClinicalTrials.gov as NCT06208150) is a randomized, Phase 3, three-arm trial in adults with relapsed or refractory multiple myeloma who had received one to four prior lines of therapy, including both an anti-CD38 antibody (such as daratumumab) and lenalidomide. According to Fierce Pharma's reporting on the release, the study population sat in the second-to-fifth-line setting, with roughly 80 percent of enrolled patients already refractory to daratumumab, meaning this is a population whose disease had already stopped responding to some of today's standard tools.

Patients were randomized to one of three arms: TECVAYLI plus TALVEY (“Tec-Tal”), the dual-bispecific combination; TALVEY plus pomalidomide (“Tal-P”); or investigator's choice of standard-of-care control — either elotuzumab plus pomalidomide plus dexamethasone (EPd), or pomalidomide plus bortezomib plus dexamethasone (PVd).

The trial's primary endpoint was progression-free survival (PFS), assessed by an independent review committee, meaning the readout was not based solely on investigators' own assessment of scans. J&J and multiple outlets that reviewed the release, including the International Myeloma Foundation and the biopharma trade press, reported the following topline figures from what J&J has described as the trial's first interim analysis: Tec-Tal versus control showed an 89 percent reduction in the risk of disease progression or death (hazard ratio 0.11; 95 percent confidence interval 0.08–0.16; p<0.0001); Tal-P versus control showed a 73 percent reduction in the risk of disease progression or death (hazard ratio 0.27; 95 percent confidence interval 0.20–0.35); and for overall survival, Tec-Tal versus control showed a 62 percent reduction in the risk of death (hazard ratio 0.38).

Those are large effect sizes by the standards of relapsed/refractory myeloma trials, and the fact that the combination cleared both the PFS and, per J&J's release, a key overall-survival analysis is what has generated the enthusiastic response from oncologists and industry press this summer. J&J's own release, together with independent verification via Fierce Pharma's separate reporting, both converge on the same 89 percent PFS figure and 62 percent OS figure for the Tec-Tal arm, which gives confidence in those specific numbers as reported.

What's Disclosed Versus What's Still Missing

It is worth being precise about the shape of what has actually been released, because a “topline” announcement is, by design, a curated summary, not a data package. Based on J&J's press release and the International Myeloma Foundation's summary of it, several things have not yet been disclosed: the total number of patients enrolled in the trial; median PFS and median OS values (the actual number of months, rather than just the relative risk reduction) for either experimental arm; overall response rate, complete response rate, and minimal residual disease (MRD)-negative complete response rate, standard secondary measures oncologists use to gauge depth of remission; a hazard ratio for the Tal-P arm's overall-survival benefit (J&J's release states only that the improvement was “statistically significant,” without the accompanying HR or confidence interval); and detailed, patient-level safety and adverse-event data beyond the topline characterization.

J&J's release states plainly that “full study results will be presented at a future medical meeting and submitted to global health authorities,” and both the company's own materials and the independent coverage reviewed describe these as first interim analysis findings. In plain terms: these numbers have not been peer-reviewed, have not appeared in a journal, and have not been presented in a session where independent oncologists could question the investigators about methodology, patient selection, or the control arm's performance. Readers should treat the 89 percent and 62 percent figures as real, company-reported, and independently corroborated across multiple outlets, but not yet validated through the peer-review process that typically follows presentation at a meeting such as ASH or ASCO.

Safety Considerations

Both TECVAYLI and TALVEY carry FDA boxed warnings, the agency's most serious label warning, for cytokine release syndrome (CRS) and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS). Both drugs are also dispensed only through a Risk Evaluation and Mitigation Strategy (REMS) program because of these risks. J&J's release characterizes the combination's safety profile as “consistent with the known safety profiles of each monotherapy,” and Fierce Pharma's reporting adds a notable wrinkle: according to J&J's own comments, the combination showed fewer infections than TECVAYLI given alone, and fewer GPRC5D-related side effects (such as skin, nail, and taste disturbances) than TALVEY given alone. If that pattern holds up when full data are presented, it would be a meaningfully reassuring result, since combining two active immunotherapies could just as easily have compounded their individual toxicities rather than moderating them. That said, this is a company characterization rather than a peer-reviewed adverse-event table, and the actual CRS and ICANS incidence and grade data should be seen before drawing firm conclusions.

Regulatory Status: What Has and Hasn't Been Approved

It is important not to conflate this topline readout with a regulatory approval. Both individual drugs already carry their own approvals: TECVAYLI was first approved by the FDA in October 2022 as a monotherapy, and a teclistamab-plus-daratumumab combination was FDA approved in March 2026 for a different indication than the one tested here. TALVEY was approved by the FDA in August 2023. Both drugs also hold approvals in Europe. But the specific Tec-Tal (TECVAYLI plus TALVEY) combination, and the Tal-P (TALVEY plus pomalidomide) combination tested in MonumenTAL-6, are not yet FDA-approved regimens for this relapsed/refractory population. J&J's release states the company intends to submit these data to global health authorities, which is the standard next step after a positive Phase 3 readout, but a regulatory filing, agency review, and any resulting label change would still need to occur before either combination is available to prescribe based on this trial. Per the coverage reviewed, J&J has also described this as the fifth positive Phase 3 result to date across its broader myeloma T-cell-engaging drug portfolio.

Why This Matters for Myeloma Patients

Multiple myeloma remains, for most patients, an incurable but increasingly manageable cancer, one where each new line of therapy after relapse has historically delivered a shorter response than the one before it. A regimen that cuts the risk of progression or death by 89 percent relative to today's standard second-through-fifth-line options, if that finding holds up under full peer review, would represent a substantial step in a treatment setting where options tend to become less effective as patients cycle through prior therapies. It is also notable that this is a combination of two agents patients could, in principle, receive without the weeks-long manufacturing wait, cell collection, and bridging chemotherapy that CAR-T therapies currently require, since bispecifics are ready-to-use rather than custom-manufactured per patient. For patients and caregivers navigating relapsed myeloma today, the realistic takeaway is one of genuine, well-corroborated optimism about where the field is heading, paired with the practical reality that this exact combination is not yet available outside of a clinical trial, and that the deeper data needed to fully evaluate it — durability of response, quality-of-life measures, and complete safety tables — are still to come.

Bottom Line

MonumenTAL-6's topline results are a genuinely encouraging development for relapsed/refractory multiple myeloma: an 89 percent reduction in progression-or-death risk and a 62 percent reduction in death risk for the TECVAYLI-plus-TALVEY combination, both figures independently corroborated across J&J's own release and separate trade-press reporting. But “topline” means exactly that. Enrollment numbers, median survival times, response-depth measures, and full safety tables have not been released; the findings have not been peer-reviewed or presented at a medical meeting; and the specific drug combination tested is not yet FDA-approved for this use. RegenMed Review will follow this story as full data are presented and as any regulatory submissions move forward.